Physician profile
Keith A Weaver
NPI 1265652317
$6,162.17
in general payments reported to CMS, 2019-2025
52 companies · $793 in 2025
The $793 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $918 · 2021: $1,159 · 2022: $1,019 · 2023: $813 · 2024: $660 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250 · Education: $15.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,250.47 |
| Education | $15.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,372.04 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $675.26 | 2019-2025 | Vraylar |
| Amneal Pharmaceuticals LLC | $276.62 | 2021-2025 | Unithroid |
| Xeris Pharmaceuticals, INC. | $275.90 | 2020-2025 | Gvoke Hypopen, Recorlev |
| Merck Sharp & Dohme LLC | $274.62 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Esperion Therapeutics, INC. | $250.18 | 2020-2025 | Nexletol |
| Insulet Corporation | $246.46 | 2019-2024 | Omnipod |
| Mannkind Corporation | $230.42 | 2022-2024 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.87 | 2020-2024 | Jardiance |
| Amgen INC. | $160.51 | 2019-2025 | Otezla, Repatha, Otezla |
| Clarus Therapeutics INC. | $154.00 | 2021 | |
| Pfizer INC. | $149.05 | 2020-2025 | |
| Lilly USA, LLC | $139.69 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Antares Pharma, INC. | $124.73 | 2022-2024 | Xyosted |
| Astrazeneca Pharmaceuticals Lp | $111.99 | 2019-2021 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.